CRISPR-Based Drug Startup Launches With Big Venture Dollars
This article was originally published in The Pink Sheet Daily
Executive Summary
A trio of high profile venture firms aims to turn a promising discovery in genetic manipulation into new pharmaceutical products, putting $43 million behind a new genome editing start-up, Editas Medicine.